Rate of human papillomavirus vaccination and knowledge of human papillomavirus literacy in secondary school students from Northern Thailand: post COVID-19 era Authors: Napat Likkasittipan, Prapaporn Suprasert Published: 2026 ABSTRACT AbstractBackgroundDuring the COVID-19 pandemic, human papillomavirus (HPV) vaccination programs and media campaigns promoting HPV literacy were disrupted. As a result, many targeted students remained unvaccinated during that period. This study aimed to evaluate HPV vaccination coverage and health literacy among secondary school students in the recent post–COVID-19 era.MethodsA cross-sectional survey was conducted between July and August 2023 among 600 students (grades 7–12) from six Thai schools in Chiang Mai, a province in northern Thailand. The study assessed HPV vaccination status and HPV-related health literacy.ResultsAmong the participants (mean age 14.9 years; 47.3% female), only 21.5% (n = 120) reported receiving the HPV vaccine, with 58.3% (n = 70) completing the full course. Government supply was the primary source of vaccination, and 92.2% of vaccinated students were female. Significant differences in health literacy were observed between vaccinated and unvaccinated students, particularly in knowledge of HPV’s association with cervical cancer, vaccine efficacy, safety, and perceived necessity. Differences were also evident regarding perceived cost, government promotion, awareness of national HPV policies, and the impact of the COVID-19 pandemic on vaccination uptake.ConclusionThis study highlights the persistently low HPV vaccination rate among secondary school students in northern Thailand, accompanied by notable disparities in health literacy. These findings underscore the urgent need for targeted interventions to improve awareness of HPV infection and vaccination, and to strengthen public health initiatives aimed at overcoming barriers and increasing vaccine uptake.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12889-026-28075-9.Keywords: HPV vaccine, HPV literacy, Secondary school students Background Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide [1]. It is estimated that about 75% of both sexually active men and women will be infected with HPV at some point in their lives [2]. The majority of HPV infections are asymptomatic and resolve spontaneously [3]. However, persistent infection with high-risk HPV accounts for approximately 95% of cancer of the cervix [1] and is associated with 70% of oropharyngeal cancers [4]. In addition, HPV infection is linked to non-malignant conditions such as genital warts and recurrent respiratory papillomatosis, both of which often recur after treatment [5]. To address this global health burden, HPV vaccines were developed and first implemented in 2006 with the bivalent vaccine (Cervarix®), followed by the quadrivalent vaccine (Gardasil®) in 2009 and the 9-valent vaccine (Gardasil 9®) in 2014 [6]. The World Health Organization (WHO) subsequently set a global goal to eliminate cervical cancer by 2030, with one of the key targets being that 90% of girls aged 9–15 years should be fully vaccinated against HPV [7]. Unfortunately, this target may not be met even in high-income countries due to vaccine hesitancy [8] and the disruptions caused by the coronavirus disease 2019 (COVID-19) pandemic [9]. Vaccine hesitancy, defined by the WHO as the “delay in acceptance or refusal of vaccination despite availability of vaccination services,” is a complex and multifactorial issue that undermines vaccination programs worldwide [10]. Contributing factors include limited knowledge about HPV and cervical cancer prevention, misconceptions about vaccine safety and efficacy, cultural or religious concerns, and mistrust of healthcare systems. In addition, misinformation spread through mass and social media has further fueled safety concerns and delayed vaccine uptake [11]. These challenges are evident in both high-income countries, where vaccination rates have plateaued, and in low- and middle-income countries (LMICs), where financial constraints and health system limitations exacerbate the problem [12]. Thus, despite the proven effectiveness of HPV vaccines, vaccine hesitancy remains a significant barrier to achieving global vaccination targets. The COVID-19 pandemic that occurred over the past 2–3 years further disrupted HPV vaccination programs for students. Contributing factors included social distancing policies, interruptions in vaccine transport, fear of contracting COVID-19, and a predominant focus of social media and public campaigns on COVID-19 vaccination. The WHO and UNICEF also reported a global decline in vaccination in 2020 [9]. For Thailand, the HPV vaccine was first introduced into the Expanded Program on Immunization (EPI) in 2017, targeting grade five schoolgirls aged 9–10 years through a school-based program. This vaccination was provided free of charge but limited only to grade five girls, and the implementation was inconsistent in some years. The program was interrupted during 2019–2021 because of the COVID-19 pandemic but was reimplemented in 2023. At that time, the Pediatric Infectious Disease Society of Thailand recommended that both boys and girls aged 9–15 years should receive two doses of the HPV vaccine. This recommendation is advisory and voluntary, rather than a mandatory national policy [13, 14]. In addition, some children may have received a third dose in accordance with earlier international recommendations or on the advice of private hospitals. The interruption of the school-based vaccination program during the COVID-19 pandemic not only reduced vaccination coverage but also likely weakened public awareness and confidence in the vaccine, as routine education and health promotion activities were disrupted. This gap may have contributed to persistent vaccine hesitancy, compounding the challenge of improving uptake even after program reimplementation. Moreover, previous studies conducted in Thailand before the COVID-19 era already indicated that HPV health literacy among the population was only at a moderate level [15]. Taken together, these factors underscore the importance of reassessing both HPV vaccination rates and HPV-related health literacy among adolescents in the post-pandemic period. Therefore, this study aimed to evaluate the HPV vaccination rate and the health literacy of HPV through a cross-sectional survey of secondary school students from northern Thailand after the outbreak of COVID-19. The results may provide evidence to inform policies designed to strengthen knowledge and improve HPV vaccine acceptance in this target group. Methods Study design and setting This was a cross-sectional study conducted between June and August 2023 in Chiang Mai Province, Thailand. Six Thai schools located in the city were purposively selected, comprising three private schools and three government schools. Study population and sampling The study included students from grades 7 to 12 who were enrolled at three private and three government Thai schools located in the city of Chiang Mai Province. Representative teachers from each participating school were briefed on the study protocol and instructed to randomly invite eligible students, ensuring proportional distribution across grades and genders. Because the randomization was conducted independently by the teachers, the exact number of students invited was not recorded. Students who could not understand the Thai language were excluded; however, since the survey was conducted in Thai schools, all participants were expected to be proficient in Thai. Ultimately, 600 students agreed to participate and completed the survey. Questionnaire development and content The questionnaire used in this study was adapted from a previous publication, with additional items included to address the impact of the COVID-19 outbreak on HPV vaccination [16]. Although the current national guideline recommends a two-dose schedule for boys and girls aged 9–15 years, a question regarding a possible third dose was also included, as some students reported receiving three doses through private healthcare or parental preference. The questionnaire was pilot-tested with a convenience sample to ensure clarity, and the complete version is provided in the supplementary file. The questionnaire consisted of three parts: Demographic data: gender, current education level, home community, underlying disease, number of family members, parents’ occupation, learning program, HPV vaccine suggestion, and average grade point average (GPA). Demographic data: gender, current education level, home community, underlying disease, number of family members, parents’ occupation, learning program, HPV vaccine suggestion, and average grade point average (GPA). Characteristics of HPV-vaccinated students. Characteristics of HPV-vaccinated students. Thirty-one items on HPV health literacy: covering HPV infection and HPV vaccination, rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). Thirty-one items on HPV health literacy: covering HPV infection and HPV vaccination, rated on a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). Each knowledge assessment item had a predetermined correct answer based on established scientific evidence and national and international HPV vaccination guidelines. Student responses were scored against these correct answers, with higher scores indicating greater HPV literacy. For interpretation, mean literacy scores were categorized into three levels: low (1.00–2.49), moderate (2.50–3.49), and high (3.50–5.00). The content of the 31 items covered three domains: (1) basic knowledge of HPV infection, including transmission routes, its association with cervical cancer, and prevention strategies; (2) knowledge and attitudes toward HPV vaccination, including efficacy, safety, and recommendations; and (3) perceptions of the COVID-19 pandemic’s impact on HPV vaccination and HPV literacy. Six of the items specifically addressed the influence of the pandemic on awareness and promotion. In addition, space was provided at the end of the questionnaire for participants to offer suggestions regarding HPV health literacy. Psychometric properties To evaluate reliability, the internal consistency of the 31-item health literacy scale was assessed using Cronbach’s alpha, which indicated acceptable reliability (α = 0.750). Sample size calculation The primary outcome of this study was the proportion of secondary school students who had received the HPV vaccine, while the secondary outcome was their level of health literacy regarding HPV. The sample size was estimated using the formula for a single proportion [17]: Assuming a 95% confidence level (Z = 1.96), an expected vaccination coverage proportion of p = 0.80 based on WHO/UNICEF global immunization coverage estimates for low- and middle-income countries [18], and a margin of error of d = 0.05, the required sample size was 246. To account for the design effect from school-based sampling, this number was multiplied by 2.0, resulting in 492. Anticipating up to 20% non-response or incomplete data, the final target sample size was approximately 600 students. This sample was stratified equally across grades 7–9 and 10–12 to ensure adequate representation of both lower and upper secondary school levels. Statistical analysis Statistical analysis was performed using IBM SPSS Statistics version 22.0 for Windows (IBM Corp., Armonk, NY, USA). Means with standard deviations or medians with ranges were calculated for descriptive analysis. The chi-square test, Fisher’s exact test, or Wilcoxon rank-sum test was applied to compare characteristics between HPV-vaccinated and non-vaccinated groups, as appropriate. The independent-samples t-test was used to compare mean HPV health literacy scores between vaccinated and non-vaccinated groups. A p-value < 0.05 was considered statistically significant. Data collection procedures After preparing the questionnaire, representative teachers from each participating school were briefed on the study protocol. They were then instructed to randomly invite eligible students from grades 7–12, ensuring proportional distribution across grades and genders. Eligible students were required to provide signed parental consent prior to participation, and verbal assent was obtained from the students before completing the questionnaire. The self-administered paper-based questionnaire was completed in classrooms under teacher supervision, which helped ensure the integrity of responses and allowed teachers to clarify instructions when needed. Upon completion, each student received 100 Thai baht (approximately 2.8 USD) as an incentive. Ethics approval and consent to participate All study procedures were conducted in accordance with the Declaration of Helsinki and were approved by the Faculty of Medicine, Chiang Mai University Research Ethics Committee (Study code: OBG-2565-09357, Research ID: 9357). Written informed consent was obtained from the parents or legal guardians of all participating students, and verbal assent was obtained from the students before participation. This study was not registered with ClinicalTrials.gov, as it did not constitute a clinical trial. The first participant was recruited on June 1, 2023. Result A total of 600 students in grades 7–12 participated in this study, with a mean age of 14.9 years; 47.3% were female. Participants were distributed across grades 7–12 in proportions of 15–20% per grade, and approximately half were enrolled in the science–mathematics program. The median grade point average for the last semester was 3.7. Approximately 16.7% of students reported having an underlying disease, most commonly an allergy. Most students lived in households with four family members, and more than 80% reported that their parents’ occupations were outside the medical field. The median parental income was 40,000 Thai baht (approximately 1,130 USD). About 20% of students reported that the HPV vaccine had been recommended to them. Detailed demographic data are presented in Table 1. Table 1Demographic data of all students (N = 600)N (%)Mean age (+ SD, range: years)14.93(1.852, 11–19)Sex Female284 (47.3) Male316 (52.7)Grade 789 (14.8) 892 (15.3) 9119 (19.8) 1090 (15.0) 1190(15.0) 12120 (20.0)Type of school Private300 (50.0) Government300 (50.0)Underlying disease*100 (16.7)Home is located in the city262 (43.7)Total family members 113(2.2) 244 (7.3) 3140 (23.3) 4225 (37.5) 5104 (17.3) > 5–974 (12.3)Father’s JobGovernment service133 (22.2) Personal business193 (32.2) Private company78 (13.0) Merchant74 (12.3) Other122 (20.3)Mother’s Job Government service121 (20.2) Personal business154 (25.7) Private company88 (14.7) Merchant109 (18.2) other123 (21.3)Parent’s career Non-medical related512 (85.3) Medical related88 (14.7)Median parent income per month (range) baht40,000 (3,000–5,000,000)Median student income per month (range) baht3,000 (60 − 50,000)Program of study Science-mathematics program306 (51.0) Art-mathematics program25 (4.2) Art-language program107 (17.8) Other162 (26.9)Median grade point average3.7 (1.89-4.00)HPV Vaccine suggestion Yes129 (21.5) No471 (78.5)*Allergy (56), G6PD (18), asthma (9),valvular heart disease (4), skeletal disease (3), Thalassemia trait (3),Thyroid disease (2), obesity (1), diabetes mellitus (1), tumor (1), pneumothorax (1), epilepsy (1) Demographic data of all students (N = 600) *Allergy (56), G6PD (18), asthma (9),valvular heart disease (4), skeletal disease (3), Thalassemia trait (3),Thyroid disease (2), obesity (1), diabetes mellitus (1), tumor (1), pneumothorax (1), epilepsy (1) Regarding HPV vaccination, only 20% of students reported receiving the HPV vaccine, the majority of whom were female. Details of vaccinated students are presented in Table 2. The median age at the first dose was 12 years, and 17.5% reported having an underlying disease. More than 80% of vaccinated students did not know the specific type of HPV vaccine they had received, and 58.3% reported completing the full series. The most common reason for vaccination was government policy, followed by parental recommendation, personal choice, and advice from healthcare providers. Only 12.5% reported minor adverse effects, most commonly tenderness at the injection site. Table 2Characteristics of HPV vaccinated students (N = 120)N (%)Median age 1st dose (year)12Gender Female113 (94.2) Male7 (5.8)Underlying disease*21 (17.5)Brand of HPV vaccine Gardasil ®9 (7.5) Gardasil-9®6 (5.0) Cervarix®3 (2.5) Unknown101 (84.2)1st dose43 (35.8)2nd dose68 (56.7)3rd dose**9 (6.8)Complete dose70 (58.3)Incomplete dose4 (3.3)Unknown39 (32.5)Ongoing7 (5.8)The reason for vaccinating Government policy67 (55.8) Own need10 (8.3) Parent need36 (30.0) Suggestion by medical career7 (5.8)Side effect15 (12.5) Yes*** No*allergy (14), asthma (2), G6PD, (2)valvular heart disease (1), thyroid disease (1), epilepsy (1)** Three-dose responses reflect student-reported vaccination through private healthcare providers or in accordance with earlier international recommendations. The current national guideline in Thailand recommends a two-dose schedule for boys and girls aged 9–15 years*** side effect: All were pain at the injected site Characteristics of HPV vaccinated students (N = 120) *allergy (14), asthma (2), G6PD, (2)valvular heart disease (1), thyroid disease (1), epilepsy (1) ** Three-dose responses reflect student-reported vaccination through private healthcare providers or in accordance with earlier international recommendations. The current national guideline in Thailand recommends a two-dose schedule for boys and girls aged 9–15 years *** side effect: All were pain at the injected site Table 3 presents the characteristics of vaccinated and non-vaccinated students. Female gender, grades 10–12, parents’ occupations outside the medical field, and higher median income were significantly more common in the vaccinated group, whereas type of school and underlying disease did not differ significantly between groups. Table 3Characteristics between vaccinated (N = 120) and unvaccinated (N = 480) HPV vaccine studentsVaccinated group (%)Non-vaccinated group (%)P-valueMean age (± SD: years)15 (± 1.72)14 (± 1.87)0.01#Sex Male7 (5.8)277 (57.7)< 0.01 Female113 (94.2)203 (42.3)Grade 7–943 (35.8)257 (53.5)< 0.01 10–1277 (64.2)223 (46.5)Type of school Government58(48.3)242 (50.4)0.76 * Private62(51.7)238 (49.6)Underlying disease Yes21 (17.5)79 (16.5)0.89 * No99 (82.5)401 (83.5)Medical-related parent job Yes26 (21.7)62 (12.9)0.02 * No94 (78.3)418 (87.1)Program of study Science-Math62 (51.7)244 (50.8)0.92 * other58 (48.3)236 (49.2)The median income of the parents (Baht)50,00040,000< 0.01!*Chi-square test, #t-test, ! Wilcoxon rank sum test Characteristics between vaccinated (N = 120) and unvaccinated (N = 480) HPV vaccine students *Chi-square test, #t-test, ! Wilcoxon rank sum test Regarding HPV health literacy, Table 4 summarizes the mean scores for all students, stratified by vaccination status. Overall, students demonstrated a moderate level of knowledge (mean score 2.50–3.49). The internal consistency of the 31-item questionnaire was acceptable, with a Cronbach’s alpha of 0.75, supporting the reliability of the instrument. Vaccinated students showed significantly higher literacy in key domains, including recognition that HPV causes cervical cancer, awareness of vaccine protection, perceptions of vaccine safety, and intentions to complete the vaccination series. In contrast, unvaccinated students were more likely to perceive the vaccine as unnecessary, unaffordable, or inadequately promoted by the government. Both groups strongly agreed that HPV vaccination should be provided free of charge. Perceptions regarding the COVID-19 pandemic indicated that many students believed it reduced vaccination uptake and weakened government promotion efforts, although some anticipated improved knowledge and stronger promotion in the post-pandemic period. Table 4Mean level of health literacy of HPV of all students stratified by status of HPV vaccinationItem / Mean (± SD)Total(N = 600)Non-HPV vaccinated students(N = 480)HPV vaccinated students (N = 120)*P-value1HPV infection causes genital wart3,32 (± 1.14)3.31 (± 1.15)3.39 (± 1.01)0.462HPV infection causes cervical cancer4.12 (± 1.03)4.03 (± 1.04)4.45 (± 0.87)< 0.013HPV infection causes oropharyngeal cancer3.14 (± 1.22)3.15 (± 1.21)3.11 (± 1.28)0.734HPV vaccine protects against genital wart3.29 (± 1.15)3.25 (± 1.14)3.45 (± 1.17)0.105HPV vaccine protects against cervical cancer4.13 (± 0.99)4.03 (± 1.01)4.53 (± 0.73)< 0.016HPV vaccine protects against oropharyngeal cancer3.24 (± 1.18)3.25 (± 1.16)3.19 (± 1.27)0.647HPV vaccine is important for female health4.37 (± 0.87)4.29 (± 0.89)4.66 (± 0.69)< 0.018HPV vaccine is important for male health3.59 (± 1.283.63 (± 1.23)3.46 (± 1.46)0.209HPV vaccine prevents HPV infection in both female and male3.85 (± 1.243.88 (± 1.21)3.73 (± 1.38)0.2410I do not plan to receive the HPV vaccine3.11 (± 1.36)3.34 (± 1.31)2.18 (± 1.13)< 0.0111I plan to complete the HPV vaccine series2.95 (± 1.33)2.67 (± 1.24)4.08 (± 1.08)< 0.0112I received a completed dose of the HPV vaccine already2.03 (± 1.60)1.61 (± 1.36)3.67 (± 1.46)< 0.0113HPV vaccine is safe3.86 (± 0.96)3.75 (± 0.96)4.30 (± 0.84)< 0.0114I have friends who have received the HPV vaccine3.06 (± 1.50)2.77 (± 1.46)4.22 (± 0.98)< 0.0115I am concerned about short-term side effects2.97 (± 1.27)2.91 (± 1.24)3.21 (± 1.37)0.0216I am concerned HPV vaccine has long-term health risks3.04 (± 1.28)3.06 (± 1.23)2.98 (± 1.44)0.5817The HPV vaccine is unnecessary2.07 (± 1.08)2.17 (± 1.11)1.64 (± 0.85)< 0.0118HPV vaccine costs more than my parents can afford2.70 (± 1.08)2.76 (± 1.06)2.44 (± 1.11)< 0.0119I don’t think I can get the full dose of the HPV vaccine2.45 (± 1.89)2.61 (± 1.18)1.81 (± 0.98)< 0.0120I think it’s hard to find a place to get a full dose of the HPV vaccine2.50 (± 1.27)2.60 (± 1.11)2.10 (± 1.01)< 0.0121I think the Thai government doesn’t have enough publicity about HPV vaccinations.3.38 (± 1.28)3.44 (± 1.14)3.14 (± 1.03)0.0122I don’t know about the national vaccine policy regarding the HPV vaccine3.59 (± 1.14)3.68 (± 1.15)3.21 (± 1.04)< 0.0123I will receive the HPV vaccine if my doctor recommends it3.77 (± 1.11)3.68 (± 1.11)4.13 (± 1.01)< 0.0124I have received enough information to make an informed decision about whether or not to receive the HPV vaccine.3.22 (± 1.23)3.07 (± 1.24)3.83 (± 1.03)< 0.0125I think Thai people should get the HPV vaccine free of charge4.36 (± 0.95)4.29 (± 0.98)4.62 (± 0.74)< 0.0126I think the COVID-19 outbreak situation decreased my knowledge about HPV infection and the HPV vaccine.3.52 (± 1.14)3.49 (± 1.14)3.64 (± 1.13)0.2027I think the COVID-19 outbreak situation affected the promotion of vaccination from the government.3.88 (± 1.02)3.85 (± 1.01)4.00 (± 1.01)0.1528I think the COVID-19 outbreak situation decreased vaccinations against HPV infection3.59 (± 1.11)3.51 (± 1.11)3.91 (± 1.01)< 0.0129I think that after the COVID-19 outbreak situation, I will gain more knowledge about HPV infection and the HPV vaccine3.29 (± 1.18)3.21 (± 1.19)3.60 (± 1.09)< 0.0130I think that after the COVID-19 outbreak situation, the promotion of HPV vaccine will be increased3.47 (± 1.14)3.38 (± 1.13)3.84 (± 1.08)< 0.0131I think that after the COVID-19 outbreak situation, more people will receive the HPV vaccine3.49 (± 1.15)3.39 (± 1.15)3.88 (± 1.08)< 0.01HPV Human papillomavirus, SD Standard deviation*Comparison between non-HPV vaccinated and HPV vaccinated students by T-test, Scale 1 = lowest, 5 = highest Mean level of health literacy of HPV of all students stratified by status of HPV vaccination HPV Human papillomavirus, SD Standard deviation *Comparison between non-HPV vaccinated and HPV vaccinated students by T-test, Scale 1 = lowest, 5 = highest Discussion The present study revealed that the HPV vaccination rate among secondary school students was only 20%, and about half of these vaccinated students had completed the full series. The vaccination rate was notably low, even in Chiang Mai, a major urban center in northern Thailand with an estimated population of approximately 1.2 million people [19]. WHO/UNICEF [18] reported national immunization coverage from 2010 to 2019, noting that 107 of 194 WHO member states had introduced HPV vaccination, including Thailand. However, only five countries (6%) achieved coverage of more than 90% for the final dose, and 22 countries (21%) achieved coverage of 75% or higher, while 35 countries (40%) reported coverage of 50% or less. Globally, WHO estimated that coverage of the final HPV dose in 2019 was only 15%, far below the target of 90% set for 2030 [7]. One main reason for the decreased global HPV vaccination rate may have been the COVID-19 pandemic. Rao et al. [20] recently reported the impact of the pandemic on Malaysia’s national HPV immunization program, which had been successfully implemented since 2010 for 13-year-old female students until the onset of the pandemic in 2020. School closures during this period resulted in approximately 225,000 target students missing their vaccination or receiving incomplete doses in 2020 and 2021. In contrast, Abouelella et al. [21] from the United States reported a different outcome. They compared HPV vaccination rates before the COVID-19 pandemic in 2019 and during the pandemic in 2020, and found a 3.6% increase in vaccine initiation (from 18,788 [71.5%] to 20,162 [75.1%] adolescents) and a 4% increase in series completion (54.2% vs. 58.6%). Interestingly, Hispanic white teens and those from high-income families had lower vaccination rates. The authors explained this finding by suggesting that families with higher socioeconomic status had a greater capacity to socially distance and were therefore less likely to seek vaccination. Another study from Korea [22] surveyed 161 women aged 20–49 years between January and June 2021 about the impact of the COVID-19 pandemic on perceptions of HPV vaccination. The results showed positive attitudes toward the HPV vaccine, with participants reporting increased belief in its efficacy. Regarding gender-neutral policy, WHO reported in 2019 that 33 of 107 countries with national HPV immunization programs provided the vaccine to both females and males. Approximately 80% of these countries were high-income, while the remaining 20% were upper-middle-income countries [18]. In the present study, only 7 out of 316 male students reported having received the HPV vaccine. Therefore, a gender-neutral policy is not yet widely adopted in Thailand. Regarding the health literacy of HPV, the mean scores among all participants indicated a moderate level (2.50–3.49 on the 5-point scale). However, vaccinated students demonstrated significantly higher literacy levels, with mean scores between 3.00 and 4.00 across most items. These findings are consistent with the study by Suryadevara et al. [16] conducted in the United States, which surveyed HPV vaccine attitudes among 415 high school students, 252 college students, and 222 healthcare professional students. That study found that healthcare professional students had greater HPV literacy than high school and college students. Although our study focused solely on high school students and thus could not directly compare across education levels, the moderate literacy levels observed in our participants correspond with the lower scores reported among high school students in that study. This underscores the importance of strengthening HPV-related education among adolescents to improve knowledge and vaccination uptake. A study from China surveyed 800 college students across four universities using self-administered questionnaires and found that only 46.7% of participants demonstrated good knowledge of cervical cancer prevention and the HPV vaccine. The authors also reported that factors such as gender, academic major, education level, father’s education, premarital sex attitudes, and mother’s cervical cancer screening history were significantly associated with HPV knowledge [23]. In contrast, a recent study from Thailand [24] assessed HPV literacy among 198 final-year medical students using electronic questionnaires and found that 70% answered fewer than 60% of the questions correctly. These findings suggest that knowledge of HPV infection and vaccination remains inadequate and should be strengthened. Interventions to improve HPV vaccination coverage were summarized in a systematic review by Mavunsza et al. [25]. The authors reviewed 35 studies, primarily from the United States, and identified several effective strategies: narrative education, outreach with reminders, reminders alone, financial incentives combined with reminders, brief motivational behavioral interventions, provider prompts, training with assessment and feedback, consultation, funding, and multicomponent interventions. The strength of the present study lies in its cross-sectional survey design, which included both male and female secondary school students in the recent post–COVID-19 period with an adequate sample size. All questionnaires were completed by students in their classrooms, ensuring that the responses reflected their actual knowledge of HPV literacy. The data revealed a very low rate of HPV vaccination, largely due to the temporary suspension of national immunization programs during the COVID-19 pandemic. However, many schools had resumed their immunization schedules, including HPV vaccination for grade 5 female students, by the time of this survey. Therefore, HPV vaccination rates are expected to increase in the near future. This study has several limitations. First, the HPV vaccination rate was based on self-reported survey data without verification against official vaccination records. However, students were encouraged to confirm this information with their parents or teachers, which likely improved recall accuracy. Second, although students who could not understand Thai were excluded, the exact number of such exclusions was not recorded, as the survey was conducted in Thai schools where all participants were expected to be proficient in Thai. Finally, the study was limited to six schools in Chiang Mai Province, which may restrict the generalizability of the findings to the broader secondary school student population in Thailand. Public health implications and future research The moderate HPV literacy and suboptimal vaccination coverage observed in this study highlight the urgent need to strengthen school-based vaccination delivery, implement targeted educational initiatives, and ensure equitable access to free HPV vaccines. Priority actions should include catch-up vaccination for cohorts missed during the COVID-19 pandemic, parental engagement to address concerns about safety and necessity, and teacher involvement in disseminating accurate health information. Future research should explore the determinants of vaccine hesitancy through qualitative approaches, evaluate the effectiveness of tailored school-based interventions, extend surveys to multiple provinces to assess generalizability, and conduct longitudinal studies to determine how improvements in literacy influence vaccine uptake and completion. Although the national guideline at the time of the study recommended a two-dose schedule for girls aged 11–12, recent WHO reports indicate that Thailand is exploring a single-dose 9-valent HPV vaccine strategy as a scalable approach to increase coverage and improve program efficiency [26]. This potential policy shift underscores the continued importance of strengthening HPV literacy among adolescents; even as vaccination schedules evolve toward simplification, maintaining high levels of awareness and acceptance remains critical for sustaining coverage gains and advancing progress toward cervical cancer elimination. Conclusion In conclusion, this survey found that HPV vaccination coverage among secondary school students in Chiang Mai remains inadequate, while overall HPV health literacy is at a moderate level. Vaccinated students consistently demonstrated higher literacy, particularly regarding cervical cancer prevention, vaccine safety, and the benefits of completing the vaccination series. These findings underscore the urgent need for policy action to strengthen school-based vaccination and education programs, ensure equitable access to free HPV vaccines, and implement targeted communication strategies to address misconceptions and reduce vaccine hesitancy. Achieving these measures will be essential to improve vaccine uptake and advance Thailand’s progress toward the WHO’s cervical cancer elimination targets. Future research, including qualitative, interventional, multi-province, and longitudinal studies, is warranted to inform sustainable program improvements. Supplementary Information Supplementary Material 1. Acknowledgements The authors would like to thank the participating schools, teachers, and students for their cooperation in this study. We also thank the Faculty of Medicine, Chiang Mai University, for providing institutional support. Abbreviations Human papillomavirus World Health Organization United Nations International Children’s Fund Expanded Program on Immunization Grade point average Coronavirus disease 2019 Low- and middle-income countries Statistical Package for the Social Sciences United States dollar Authors’ contributions P.S., N.L. conceived the presentation idea. N.L. collected the data. P.S. verified the analytical methods. P.S., N.L. discussed the results and contributed to the final manuscript. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Data availability The data supporting the findings of this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate Methods were conducted in accordance with the Declaration of Helsinki. All study procedures were approved by the Faculty of Medicine, Chiang Mai University Research Ethics Committee (Study code: OBG-2565-09357, Research ID: 9357). Written informed consent was obtained from all participants’ parents prior to participation, and verbal assent was obtained from the students themselves before completing the questionnaire. This study was not registered with ClinicalTrials.gov as it was not a clinical trial. The first participant was recruited on June 1, 2023. Consent for publication Not applicable. No identifiable individual data are included in this article. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Citations Supplementary Materials Supplementary Material 1. Data Availability Statement The data supporting the findings of this study are available from the corresponding author upon reasonable request.